ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biological Chemistry

WuXi, Regulus join for oligonucleotides

by Rick Mullin
March 5, 2018 | APPEARED IN VOLUME 96, ISSUE 10

WuXi AppTec’s STA Pharmaceutical contract manufacturing business and Regulus Therapeutics have launched an oligonucleotide synthesis and manufacturing collaboration. STA will work with the biotech firm on preclinical and clinical programs for microRNA-targeting drugs used to treat unspecified diseases. Regulus will provide technical support and training for the Chinese firm on oligonucleotide scale-up. STA recently established oligo labs in San Diego and Changzhou, China. The company plans to open an oligo-manufacturing facility in Changzhou this year.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment